Calquence (Acalabrutinib) for Leukemia | MyLeukemiaTeam

Connect with others who understand.

sign up Log in
About MyLeukemiaTeam
Powered By

Calquence is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat people with mantle cell lymphoma (MCL) who have received at least one prior therapy. Calquence is sometimes prescribed off-label to treat leukemia. Calquence is also referred to by its drug name, acalabrutinib.

Calquence is a member of a class of drugs called tyrosine kinase inhibitors. Calquence is believed to work by blocking the growth of cancer cells.

How do I take it?
Prescribing information states that Calquence is taken orally every 12 hours.

Calquence comes in the form of an oral capsule. It should be taken exactly as prescribed by a physician.

Side effects
The FDA-approved label for Calquence lists common side effects including low blood counts, headache, diarrhea, fatigue, muscle pain, and bruising.

Rare but serious side effects listed for Calquence include serious infections, bleeding problems, severe low blood cell counts, other cancers, and heart rhythm problems.

For more details about this treatment, visit:

Calquence — AstraZeneca

Calquence — Medscape

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in